华大基因
(300676)
| 流通市值：190.97亿 | | | 总市值：192.01亿 |
| 流通股本：4.16亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,673,638,742.11 | 1,631,472,352.82 | 671,910,156.79 | 3,866,920,764.06 |
| 营业收入 | 2,673,638,742.11 | 1,631,472,352.82 | 671,910,156.79 | 3,866,920,764.06 |
| 二、营业总成本 | 2,563,396,603.57 | 1,552,863,244.58 | 708,704,349.71 | 4,258,391,381.38 |
| 营业成本 | 1,524,833,168.33 | 903,092,164.75 | 379,323,920.01 | 2,263,225,007.91 |
| 税金及附加 | 15,011,728.22 | 7,539,175.62 | 2,734,548.46 | 19,837,665.52 |
| 销售费用 | 545,729,423.14 | 336,523,086.25 | 162,730,574.57 | 1,009,984,667.46 |
| 管理费用 | 211,678,576.06 | 142,806,963.64 | 74,058,055.43 | 409,508,019.59 |
| 研发费用 | 332,812,703.86 | 227,606,241.47 | 117,331,387.43 | 606,174,523.75 |
| 财务费用 | -66,668,996.04 | -64,704,387.15 | -27,474,136.19 | -50,338,502.85 |
| 其中:利息费用 | 16,921,050.33 | 11,350,042.82 | 3,427,131.5 | 52,019,192.87 |
| 其中:利息收入 | 71,166,396.96 | 50,355,487.19 | 25,882,047.72 | 125,718,627.31 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 17,118,766.81 | 9,210,174.71 | 6,315,979.8 | -33,175,650.35 |
| 加:投资收益 | 22,010,835.92 | 18,665,756.39 | 3,416,203.88 | -43,626,260.23 |
| 资产处置收益 | -883,888.42 | -1,785,189.01 | -1,463,943.63 | -631,684.81 |
| 资产减值损失(新) | -8,899,289.67 | -7,094,614.66 | -3,031,168.63 | -242,207,529.14 |
| 信用减值损失(新) | -187,591,909.42 | -116,808,325.93 | -37,736,301.01 | -196,237,159.27 |
| 其他收益 | 12,199,088.27 | 8,460,197 | 3,119,666.43 | 32,581,142.88 |
| 四、营业利润 | -35,804,257.97 | -10,742,893.26 | -66,173,756.08 | -874,767,758.24 |
| 加:营业外收入 | 1,757,425.28 | 1,465,311.21 | 394,233.06 | 1,973,255.22 |
| 减:营业外支出 | 11,975,498.58 | 4,037,188.92 | 3,538,252.63 | 13,320,289.83 |
| 五、利润总额 | -46,022,331.27 | -13,314,770.97 | -69,317,775.65 | -886,114,792.85 |
| 减:所得税费用 | -19,791,439.13 | -17,459,517.16 | -14,022,369.71 | 25,986,290.31 |
| 六、净利润 | -26,230,892.14 | 4,144,746.19 | -55,295,405.94 | -912,101,083.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -26,230,892.14 | 4,144,746.19 | -55,295,405.94 | -912,101,083.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -21,386,988.41 | 5,778,221.12 | -52,695,120.08 | -902,690,862.44 |
| 少数股东损益 | -4,843,903.73 | -1,633,474.93 | -2,600,285.86 | -9,410,220.72 |
| 扣除非经常损益后的净利润 | -66,764,682.44 | -30,488,145.05 | -63,297,061.5 | -918,912,270.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | 0.01 | -0.13 | -2.19 |
| (二)稀释每股收益 | -0.05 | 0.01 | -0.13 | -2.19 |
| 八、其他综合收益 | -37,070,538.01 | -38,260,529.88 | -7,717,600.05 | 38,560,810.66 |
| 归属于母公司股东的其他综合收益 | -35,540,894.17 | -36,730,419.5 | -7,923,029 | 32,098,963.66 |
| 九、综合收益总额 | -63,301,430.15 | -34,115,783.69 | -63,013,005.99 | -873,540,272.5 |
| 归属于母公司股东的综合收益总额 | -56,927,882.58 | -30,952,198.38 | -60,618,149.08 | -870,591,898.78 |
| 归属于少数股东的综合收益总额 | -6,373,547.57 | -3,163,585.31 | -2,394,856.91 | -2,948,373.72 |
| 公告日期 | 2025-10-24 | 2025-08-23 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |